Apixaban significantly reduces stroke risk in people with subclinical atrial fibrillation and prior stroke history.

Shares of Sun Pharmaceutical Industries Ltd., India's largest drugmaker, opened with gains of as much as 3% on Saturday, February 1, and are the top gainers on the Nifty 50 index after the company ...

It declared an interim dividend of Rs 5 per share. Sun Pharmaceuticals Industries: The drug major reported a 15 per cent YoY growth in its net profit at Rs 2,903.4 crore, while revenue inched up ...

Sun Pharma delivered a strong Q3 performance, surpassing Street expectations. However, concerns over the uncertain launch timeline of its hair loss drug Leqselvi and a cut in R&D spending have led ...

Indian stock markets are open today, Saturday, February 1, due to Budget Day. In the previous session on Friday, benchmark indices extended their winning streak to four consecutive sessions ...

Sun Pharma Q3 Results: Sun Pharmaceutical Industries on Friday said its consolidated net profit increased 15 per cent on-year to Rs 2,903 crore in the December quarter, riding on robust sales across ...

AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of the budget announcements. Stocks including ONGC, Sun Pharma, IndusInd Bank, Nestle, Tata Power, Waaree Energies, IRB Infra ...

Sun Pharma's Q3FY25 net profit rose 15% YoY to ₹2,903 crore, driven by strong domestic and global specialty sales. Revenue grew 10.5%, while EBITDA surged 15.3% with improved margins. The company ...

Sun Pharma Q3 Results: The company has also declared an interim dividend of Rs 10.5 per share for the financial year 2024-25. Sun Pharma on Friday reported 15% year-on-year (YoY) to Rs 2,903 crore in ...

Shares of Sun Pharma Ltd., India's largest drugmaker gained as much as 1.3% after declining as much as 2% when it reported its December quarter results. The stock gained despite its US formulation ...

The launch timeline of Sun Pharma's specialty drug Leqselvi (deuruxolitinib) continues to be stuck in a limbo even after two quarters since it got embroiled in a patent dispute. The drug ...

India’s largest drug-maker Sun Pharmaceutical Industries posted a 15 per cent year-on-year (Y-o-Y) growth in its consolidated net profit at Rs 2,903.3 crore for the third quarter of the current ...